Long-term Reduction of Relapse Rate and Confirmed Disability progression after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis

S. L. Hauser,B. Brochet, X. Montalban, R. T. Naismith, J. S. Wolinsky, M. Manfrini, M. Garas,P. Villoslada, F. Model, S. Hubeaux, L. Kappos